Flow-reversal device for cerebral protection during carotid artery stenting : acute and long-term results

Hintergrund—Derzeit können verschiedene Embolieprotektionssysteme bei der Carotis Stentimplantation angewandt werden. Diese Studie berichtet über Ergebnisse unter Verwendung des Flussumkehrsystems Parodi Anti-Embolie System. Patienten—Eine Carotis Stentimplantation wurde bei 56 Patienten durchgeführt (Durchschnittsalter 68 ± 9 Jahre). Der mittlere Stenosedurchmesser betrug 77% ± 10%. Während des Eingriffs wurde eine cerebrale Embolieprotektion mittels Ballonokklusion der Arteria carotis communis und externa mit dem Parodi Anti-Embolie System angewandt. Während der Stentimplantation, vor der Entlassung und 1, 6 und 12 Monate nach dem Eingriff wurde der neurologische Status der Patienten erhoben. Ergebnisse—Der Eingriff war bei allen Patienten technisch erfolgreich. Ein Patient entwickelte einen ischämischen Insult nach 6 Stunden. Es wurden keine Todesfälle oder Myokardinfarkte beobachtet. Während der Verlaufsbeobachtung (bis zu 40 Monate) starben 2 Patienten an einer sekundären Komplikation nach intrakranieller Blutung und ein weiterer Patient an Kammerflimmern. Bei keinem Patienten trat eine höhergradige Restenose auf. Schlussfolgerung—Die Akutergebnisse zeigen, dass die Flussumkehr bei der Carotis Stentimplantation eine sichere und effektive Methode der cerebralen Embolieprotektion darstellt. Die niedrige Komplikations- und Restenoserate entspricht den Ergebnissen in anderen Veröffentlichungen und zeigt, dass die Ballonokklusion keine Gefäßverletzungen verursacht.Objectives—Several types of cerebral (embolic) protection devices have been used in patients undergoing carotid stenting. This study assessed results achieved with a flow-reversal system. Methods—Carotid stenting was performed in 56 patients (mean age, 68 ± 9 years). The mean percentage of stenosis was 77 ± 10 %. During the procedure, cerebral protection was achieved by means of balloon occlusion of the common and external carotid artery with use of the Parodi Anti-Emboli System. The patients’ neurologic status was assessed during the intervention; at discharge; 1, 6, and 12 months after the procedure; and yearly thereafter. Results—The procedure was technically successful in all cases. One patient had a minor stroke 6 hours after the intervention. No major strokes, deaths, or myocardial infarctions occurred. During long-term follow-up (to 40 months), two patients died of a secondary complication after intracerebral bleeding and stroke and one died as a result of ventricular fibrillation. Restenosis did not exceed 50 % of vessel diameter in any patient. Conclusions—The results indicate that proximal occlusion and flow reversal for cerebral protection during carotid stenting is a safe and effective method. Restenosis and complications during long-term follow-up are rare

Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: A randomized, double-blind, placebo-controlled study

Purpose: To investigate the efficacy of prednisone for treatment of withdrawal headache in patients with medication overuse headache (MOH). Patients and methods: In this prospective double-blind, placebo-controlled, parallel designed multicentre trial, 96 consecutive patients with MOH were randomized to withdrawal treatment with either 100 mg prednisone or placebo over 5 days. Patients were enrolled if they met the International Headache Society criteria for MOH and were diagnosed with migraine or episodic tension-type headache as primary headache. Exclusion criteria comprised significant neurological or psychiatric disorders. Withdrawal symptoms, including headache severity and intake of rescue medication, were documented for 14 days after randomization. Results: Patients treated with prednisone did not experience fewer hours of moderate or severe headache than patients receiving placebo. However, patients requested less rescue medication within the first 5 days. Conclusions: During withdrawal in MOH, prednisone reduces rescue medication without decreasing the severity and duration of withdrawal headache

Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: A randomized, double-blind, placebo-controlled study

Purpose: To investigate the efficacy of prednisone for treatment of withdrawal headache in patients with medication overuse headache (MOH). Patients and methods: In this prospective double-blind, placebo-controlled, parallel designed multicentre trial, 96 consecutive patients with MOH were randomized to withdrawal treatment with either 100 mg prednisone or placebo over 5 days. Patients were enrolled if they met the International Headache Society criteria for MOH and were diagnosed with migraine or episodic tension-type headache as primary headache. Exclusion criteria comprised significant neurological or psychiatric disorders. Withdrawal symptoms, including headache severity and intake of rescue medication, were documented for 14 days after randomization. Results: Patients treated with prednisone did not experience fewer hours of moderate or severe headache than patients receiving placebo. However, patients requested less rescue medication within the first 5 days. Conclusions: During withdrawal in MOH, prednisone reduces rescue medication without decreasing the severity and duration of withdrawal headache